Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Imugene ( (AU:IMU) ) has provided an announcement.
Imugene Limited has applied to the Australian Securities Exchange for quotation of 40,906 new fully paid ordinary shares. The new securities, issued on 19 March 2026 following the exercise or conversion of existing instruments, modestly expand the company’s listed capital base and reflect ongoing utilisation of equity-linked incentives.
While the size of the new issue is relatively small in the context of Imugene’s total shares on issue, it underscores continuing shareholder and optionholder engagement with the company’s capital structure. The additional quotation maintains liquidity in the stock and signals incremental capital formation to support Imugene’s broader development and commercialisation activities.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.18 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is an Australian-listed biotechnology company focused on developing innovative immunotherapies. The company’s primary activities involve researching and progressing novel treatments, particularly in oncology, aimed at harnessing the immune system to target cancer, positioning it within the competitive global biopharmaceutical sector.
Average Trading Volume: 1,497,604
Technical Sentiment Signal: Sell
Current Market Cap: A$56.27M
Learn more about IMU stock on TipRanks’ Stock Analysis page.